key: cord-0980157-sl6i2rbo
authors: Khera, R.; Mortazavi, B.; Sangha, V.; Warner, F.; Young, H. P.; Ross, J. S.; Shah, N. D.; Pollock, B. D.; Wang, K.; Brandt, C. A.; Lin, Z.; Krumholz, H. M.; Schulz, W. L.
title: Accuracy of Computable Phenotyping Approaches for SARS-CoV-2 Infection and COVID-19 Hospitalizations from the Electronic Health Record
date: 2021-03-20
journal: medRxiv
DOI: 10.1101/2021.03.16.21253770
sha: 72a8db493253b9ae35174d9936de67fca0cdbc19
doc_id: 980157
cord_uid: sl6i2rbo

Objective: Real-world data, including administrative claims and electronic health record (EHR) data, have been critical for rapid-knowledge generation throughout the COVID-19 pandemic. Many studies relied on these data to identify cases and ascertain outcomes., commonly using diagnostic codes. However, to ensure high-quality results are delivered to guide clinical decision making, guide the public health response, and characterize the response to interventions, it is essential to establish the accuracy of these approaches for case identification of infections and hospitalizations. Methods: Real-world EHR data were obtained from the clinical data warehouse and computational health platform at a large academic health system that includes 5 regional hospitals in Connecticut and Rhode Island and their associated ambulatory practices. Demographic information, diagnosis codes, SARS-CoV-2 nucleic acid and antigen testing results, and visit data including discharge disposition were obtained from our OMOP common data model for all patients with either a positive SARS-CoV-2 test or ICD-10 diagnosis of COVID-19 (U07.1) between April 1, 2020 and March 1, 2021. Various computable phenotype definitions using combinations of test results and diagnostic codes were evaluated for their accuracy to identify SARS-CoV-2 infection and COVID-19 hospitalizations. The association with each phenotype was further compared with case volumes and, for hospitalizations, in-hospital mortality. We conducted a quantitative assessment with a manual chart review for a sample of 40 patients who had discordance between diagnostic code and laboratory result findings. Results: There were 69,423 individuals with either a diagnosis code or a laboratory diagnosis of a SARS-CoV-2 infection. Of these, 61,023 individuals had a principal or a secondary diagnosis code for COVID-19 and 50,355 had a positive SARS-CoV-2 PCR or antigen test. Among those with a positive PCR, 38,506 (76.5%) also had a principal and 3449 (6.8%) a secondary diagnosis of COVID-19, but 8400 (16.7%) had no COVID-19 diagnosis in the medical record. Moreover, of the 61,023 patients who had a COVID-19 diagnosis, 19,068 (31.2%) did not have a positive laboratory test for SARS-CoV-2 in the EHR. In a manual chart review of this sample of patients, we found that these many had a COVID-19 diagnosis code added during healthcare encounters related to asymptomatic testing, either as part of a screening program or following exposure, but with negative subsequent test results. The positive predictive value (precision) and sensitivity (recall) of a COVID-19 diagnosis in the medical record for a positive SARS-CoV-2 PCR were 68.8% and 83.3%, respectively. Further, among 5,109 patients who were hospitalized with a principal diagnosis of COVID-19, 4843 (94.8%) had a positive SARS-CoV-2 PCR or antigen test within the 2 weeks preceding hospital admission or during hospitalization. In a random sample of 10 without a positive test during the index hospitalization selected for manual chart review, 7 (70.0%) had been tested at an outside laboratory before admission and the remaining had a strong clinical suspicion for COVID-19. In addition, 789 hospitalizations had a secondary diagnosis of COVID-19, of which 446 (56.5%) had a principal diagnosis that was consistent with severe clinical manifestation of COVID-19 (e.g., sepsis or respiratory failure). Compared with the cohort that had a principal diagnosis of COVID-19, those with a secondary diagnosis more frequently male and White and had more than 2-fold higher in-hospital mortality (13.2% vs 28.0%, P<0.001). Conclusions: In a large integrated health system, COVID-19 diagnosis codes were not adequate for case identification and epidemiological surveillance of SARS-CoV-2 infection. In contrast, a principal diagnosis of COVID-19 diagnosis consistently identified hospitalized patients with the disease but missed nearly 10% of cases that presented with more severe manifestations of disease and had over 2-fold higher mortality. Data from the EHR can provide additional data elements compared to administrative claims alone, such as laboratory testing results, that can be used to in conjunction with diagnostic codes to create more fine-tuned phenotypes that are designed for specific analytical use cases.

a positive laboratory test for SARS-CoV-2 in the EHR. In a manual chart review of this sample of patients, we found that these many had a COVID-19 diagnosis code added during healthcare encounters related to asymptomatic testing, either as part of a screening program or following exposure, but with negative subsequent test results. The positive predictive value (precision) and sensitivity (recall) of a COVID-19 diagnosis in the medical record for a positive SARS-CoV-2 PCR were 68.8% and 83.3%, respectively. Further, among 5,109 patients who were hospitalized with a principal diagnosis of COVID-19, 4843 (94.8%) had a positive SARS-CoV-2 PCR or antigen test within the 2 weeks preceding hospital admission or during hospitalization.

In a random sample of 10 without a positive test during the index hospitalization selected for manual chart review, 7 (70.0%) had been tested at an outside laboratory before admission and the remaining had a strong clinical suspicion for COVID-19. In addition, 789 hospitalizations had a secondary diagnosis of COVID-19, of which 446 (56.5%) had a principal diagnosis that was consistent with severe clinical manifestation of COVID-19 (e.g., sepsis or respiratory failure).

Compared with the cohort that had a principal diagnosis of COVID-19, those with a secondary diagnosis more frequently male and White and had more than 2-fold higher in-hospital mortality (13.2% vs 28.0%, P<0.001).

In a large integrated health system, COVID-19 diagnosis codes were not adequate for case identification and epidemiological surveillance of SARS-CoV-2 infection. In contrast, a principal diagnosis of COVID-19 diagnosis consistently identified hospitalized patients with the disease but missed nearly 10% of cases that presented with more severe manifestations of disease and had over 2-fold higher mortality. Data from the EHR can provide additional data elements compared to administrative claims alone, such as laboratory testing results, that can be used to in conjunction with diagnostic codes to create more fine-tuned phenotypes that are designed for specific analytical use cases.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ;  https://doi.org/10.1101/2021.03. 16.21253770 doi: medRxiv preprint

The COVID-19 pandemic has led to the rapid adoption of real-world evidence to guide the treatment of and the public health response to a novel pathogen. [1] [2] [3] [4] [5] The identification of both SARS-CoV-2 infection and COVID-19 hospitalization is of current clinical and regulatory importance, given the need for case identification for epidemiologic surveillance to track the infections, mortality, and vaccine effectiveness. Similarly, clinical predictive models that rely on appropriate case classification and studies that track the long-term effects of SARS-CoV-2 infection may be biased if case definitions are imprecise or capture only subsets of individuals infected with SARS-CoV-2. Administrative data represent a widely available real-world data source to monitor COVID-19 cases and hospitalizations using diagnosis codes.

Administrative data are generated from billing claims and can be used to assess changes in disease epidemiology, hospitalization rates, and patient outcomes on a large scale. [6] [7] [8] [9] [10] However, reliance on claims alone may lead to erroneous inferences, as has been shown for other conditions. [11 12] To ensure that high-quality data guide national policy and biomedical research, there is a need to evaluate the accuracy of the diagnostic code-based approaches used to define cases of SARS-CoV-2 infection and hospitalization.

The adoption of health information technology systems has positioned health systems to allow such validation by incorporating more detailed clinical data from the electronic health record (EHR) with diagnosis codes, which allows for the development of more robust computable phenotypes. [13] [14] [15] [16] [17] [18] While there remain concerns about the use of EHR data given potential inaccuracies in data and risk for missing data, these issues are also reflected in data derived from them, such as administrative databases. As such, the EHR represents a potential advance over the use of administrative data alone for both case identification and phenotype validation.

In this study from a large health system with academic and community-based practices, we evaluate the accuracy of various computable phenotypes to identify SARS-CoV-2 infection . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.16.21253770 doi: medRxiv preprint and COVID-19 hospitalizations based on diagnostic codes and laboratory testing results extracted from the EHR and assess the impact of cohort selection on the identified mortality rates in those hospitalized for COVID-19.

We used EHR derived data from Yale New Haven Health System, a single academic health system consisting of 5 distinct hospital delivery networks and associated outpatient clinics located in Connecticut and Rhode Island. Data from our EHR clinical data warehouse were transformed into the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) using our computational health platform. [13 19] We used a versioned extract of the OMOP data from March 3, 2021 and analyzed testing and discharge information from April 1, 2020, when the COVID-19 specific diagnosis was introduced, through March 1, 2021.

Admissions were limited to those with a visit start date prior to January 31, 2021 to allow for a majority of those admitted to reach discharge based on our prior data which defined median length of stay for discharge patients. [3] The study was approved by the Yale University Institutional Review Board (IRB # 2000027747).

We defined two strategies to identify SARS-CoV-2 infection from the EHR spanning all healthcare settings, the first based on diagnostic codes and the second based on laboratory testing. Our first approach relied on the identification of the specific COVID-19

International Classification of Diseases-10 th Edition-Clinical Modification (ICD-10-CM) diagnosis code U07.1 within the clinical record. We used the ICD-10-CM code as opposed to the corresponding SNOMED codes in the standard OMOP vocabulary given the wider use of ICD-. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.16.21253770 doi: medRxiv preprint 10-CM in administrative data. The U07.1 code was used to define SARS-CoV-2 when used either as (1) a principal diagnosis, or a (2) a principal or a secondary diagnosis of COVID-19 during any healthcare encounter. The principal diagnosis was defined based on the standard OMOP condition status concept code, 32902. [20] The two diagnosis-based phenotyping strategies were compared to the second approach which was based on the presence of a positive SARS-CoV-2 PCR or antigen test to identify individuals who had documented infection, with manual chart abstraction of samples drawn from discordant subsets to assess the reason for differences. We supplemented this assessment to include potentially related but non-specific diagnoses for severe acute respiratory syndrome (SARS) or coronavirus disease (COVID-19-related diagnoses) based on a subset of codes identified within the National COVID Cohort Collaborative (N3C) phenotype (see eTable 1 in the Online Supplement). [21] COVID-19 hospitalization: We defined COVID-19 hospitalizations using two strategies. The first identified all hospitalizations with a principal diagnosis of COVID-19 (U07.1). In addition, we defined a second strategy that included individuals with a secondary diagnosis of COVID-19, but with a clinical presentation that was consistent with severe manifestations of COVID-19 defined by a principal diagnosis for acute respiratory failure, pneumonia or sepsis. These approach focuses on hospitalizations that were due to COVID-19 rather than incidentally associated with a positive test for the disease during screening. The principal diagnoses used in this approach are included in eTable 2. There was only a single hospitalization with a diagnosis code J12.82 that has been suggested to identify COVID-19 pneumonia, [21] and was not included in the analysis. Similar to the diagnosis-based infection identification, diagnosis codes were compared against positive SARS-CoV-2 testing 2 weeks before hospitalization through any time before hospital discharge.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.16.21253770 doi: medRxiv preprint

We defined key demographic characteristics for individuals, including age, sex, race and ethnicity. Age was defined as completed years on the day of admission, computed from their date of birth. Sex, race and ethnicity were self-reported. To evaluate the effect of coding strategies on case identification among racial and ethnic minorities, we combined racial/ethnic groups into mutually exclusive groups of Hispanic, non-Hispanic White, non-Hispanic Black, and other race/ethnicity groups. [22 23] 

Among patients hospitalized with COVID-19, we evaluated differences in mortality across case identification strategy. Mortality was defined based on the discharge disposition of the first COVID-19 hospitalization. Consistent with other studies, [24] [25] [26] we used a composite endpoint of in-hospital mortality, transfer to inpatient hospice or discharge to facility or home-based hospice to define our outcome of early mortality.

We compared difference in demographic characteristics using the chi-square test for categorical variables and t-test for continuous variables. To assess the performance of COVID-19 diagnoses accurately identifying cases of SARS-CoV-2 infection, we assessed 3 key performance measures, precision (positive predictive value), recall (or sensitivity), and area under the precision recall curve (AUPRC). [27 28] Inpatient hospitalizations were identified the diagnostic strategies outlined above. We explicitly identified the proportion of patients in the two COVID-19 hospitalization groups, those with a principal diagnosis of COVID-19 and those with a secondary diagnosis of COVID-19. We evaluated the implications of case identification strategies on representativeness of the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Analyses were conducted using Spark 2.3.2, Python 3.6.9, and R 3.8. All statistical tests were 2-tailed with a level of significance set at 0.05.

Manual chart abstraction was conducted by 2 clinicians independently (RK and WLS) and

focused on a sample of randomly selected charts where the diagnosis codes were discordant from laboratory results. For SARS-CoV-2 infections, 10 patient charts were randomly selected from each of the following categories: (1) principal diagnosis of COVID-19, but negative laboratory diagnosis, (2) secondary diagnosis of COVID-19 but negative laboratory diagnosis, and (3) a positive laboratory diagnosis of SARS-CoV-2 without a corresponding diagnosis code.

Furthermore, 10 charts were selected for patients who were hospitalized with a principal diagnosis COVID-19 and negative laboratory results, and the clinical documentation was qualitatively reviewed to evaluate the reason for the discrepancy. Table 1) .

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The characteristics of patients in these groups are included in Table 1 . There were significant differences in concordance between phenotyping strategies during the study period (Figure 3 ). Among patients with either a diagnosis code for COVID-19 or a laboratory diagnosis of SARS-CoV-2, 51% of patients had both a diagnosis code and a positive laboratory test between April and August 2020, but 65% of patients had both present . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03. 16.21253770 doi: medRxiv preprint between September 2020 and March 2021 (P<0.001). There were significant differences across racial and ethnic groups (Figure 4A) . Among Hispanics and non-Hispanic Black patients, 69.5% and 68.7% patients, respectively had both a diagnosis of COVID-19 and a positive laboratory test, compared with 54.5% of non-Hispanic White patients (P<0.001). There was also a significant difference by sex, with more women compared with men had a concomitant diagnosis code and positive laboratory test (61.4% vs 59.1%, P<0.001) (Figure 4B ).

Based on visit start date, there were a total of 5,555 discharges based on our overall phenotyping strategy between April 1, 2020 and January 31, 2021. Of these, 5,109 (92.0%) discharges had a principal diagnosis of COVID-19 and the remaining 446 had a primary diagnosis that could be associated with a severe presentation with a secondary diagnosis of COVID-19 on the same visit. Finally, there were 343 individuals who had a secondary, but not primary, diagnosis of COVID-19 which were excluded from analysis as these may indicate either incidental findings or hospital-acquired infections.

A vast majority of patients had a positive SARS-CoV-2 PCR or antigen test during the hospitalization, across both patients hospitalized with a COVID-19 primary diagnosis (94.8%, n=4843) or a secondary diagnosis (91.9%, n=410). A manually abstracted sample of 10 charts of hospitalized individuals without a positive laboratory test but a principal diagnosis of COVID during the test identified that 7 of these patients had a positive COVID-19 test at another healthcare facility prior to presentation and 3 had a strong clinical suspicion for COVID-19 but a negative PCR test.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The in-hospital mortality rate for those hospitalized with a principal diagnosis of COVID-19 was 13.2% (675 of 5,109), which was significantly lower than those with a secondary diagnosis of COVID-19 and related primary diagnosis code for sepsis or respiratory failure, who had an inhospital mortality rate that was nearly double (28.0%, 125 of 446, P<0.001) ( Table 2) . Those with a COVID-19 primary diagnosis were less frequently male (50.9% vs 59.6%, P <0.001) and

were more frequently Black (20.9% vs 17.3%, P = 0.02).

In a large integrated health system with 5 hospital care delivery networks and their outpatient clinics, COVID-19 diagnosis codes were not adequate for case identification and epidemiological surveillance of SARS-CoV-2 infection. In contrast, a principal diagnosis of COVID-19 diagnosis consistently identified patients with the disease, though would miss nearly 10% of cases who presented with a clinical disease consistent with COVID-19, but only with a secondary diagnosis of COVID-19. A focus on primary diagnosis of COVID-19 to identify hospitalizations is likely to miss this high-risk group, who had an over 2-fold higher mortality than patients with principal diagnosis of COVID-19. In an assessment spanning outpatient and inpatient settings, there was substantial discordance in a diagnosis code and a laboratory diagnosis of SARS-CoV-2 infection with 1 in 3 patients with a COVID-19 diagnosis without a SARS-CoV-2 infection based on laboratory testing, and 1 in 5 with a positive SARS-Cov-2 PCR or antigen test without any corresponding diagnosis codes.

To our knowledge, in the largest study leveraging the EHR, rather than administrative claims, to evaluate COVID-19 phenotypes across outpatient and inpatient healthcare settings across an entire year. Moreover, in addition to identifying the accuracy of phenotypic definitions, we evaluate the association of phenotype definitions on inferred short-term outcomes. Previous investigations highlighted that the COVID-19 diagnosis code, U07.1 was rapidly incorporated into the workflow of US hospitals in early 2020, [29] and among hospitalized patients, with a high . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.16.21253770 doi: medRxiv preprint sensitivity and specificity of the code for laboratory confirmed disease. However, the study was limited in using data only through May 2020, with only 4965 SARS-CoV-2 positive laboratory tests, with the accuracy measures drive by the 89.6% of the cohort that did not have either a positive test or a diagnosis code for COVID-19. [29] We confirm that an inpatient diagnosis of COVID-19 has retained a large positive predictive value for clinical COVID-19. However, we found significant heterogeneity in outcomes based on whether COVID-19 was included as a principal or a secondary diagnosis. Moreover, the study evaluating COVID-19 diagnosis codes focused exclusively among hospitalized patients and with did not evaluate the role of diagnosis codes in case surveillance.

A notable strength of our approach based on the EHR is the ability to gain additional insights into the mechanism behind discordance between diagnosis codes and laboratory results through manual chart review. This allowed us to carefully define a cohort of patients of COVID-19 consistent with its clinical definition. Moreover, it also allowed us to exclude patients who do not have COVID-19 despite a secondary diagnosis as well as a positive SARS-CoV-2 test, as during the pandemic many clinical representations (such as presentations for trauma), did in fact have an incidental positive SARS-CoV-2 screen without clinical disease. [3] Moreover, our study population includes a large racially and ethnically diverse group, allowing our study to uncover patterns of differential performance of diagnosis codes for case surveillance in racial/ethnic minority groups, in whom the presence of diagnosis codes more accurately aligned with laboratory confirmed disease.

There are many possible reasons for the incorrect classification of infections by diagnosis codes. Many studies have shown the apparent inaccuracy of various EHR data elements, such as the clinical history and problem list. [30 31] Clinical uncertainty related to a diagnosis, potential stigma associated with the addition of a diagnosis to the medical record, clinical workflows that do not promote the capture of structured data elements, and miscoded diagnoses can all impact the ability to define a digital phenotype that accurately identifies . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.16.21253770 doi: medRxiv preprint patients. [30 32 33] Moreover, diagnosis codes are often included when evaluating a suspected condition and may be misconstrued as a proof of the diagnosis, particularly in data captured in real-time. Our study highlights the value of health information systems in disease monitoring through logical cohort definitions, which can be explicitly confirmed across different data streams. Moreover, our work complements the continuous monitoring and validation of claimbased diagnoses that is essential for valid inference from a large number of investigations that rely on these ubiquitous data. A unique aspect of our approach is the availability of all EHR data in the OMOP CDM that is updated daily, allowing rapid and serially updated assessment of such cohort definitions and disease surveillance over the course of the pandemic, allowing the most up-to-date assessment of specific patient populations in a rapidly evolving condition and their outcomes.

Our study has certain limitations. First, while we focus on a broad interconnected health system and affiliated laboratories and receive testing information from laboratories that are connected to the Epic EHR, it is possible that some of the non-participating laboratory data are not available from testing in the outpatient setting. However, in manual chart review of a sample of patients with a diagnosis of COVID-19 without a reported positive PCR or antigen test by 2 clinicians, all such records were for patients undergoing SARS-CoV-2 testing with the diagnosis assigned for the clinical or laboratory encounter to obtain the test. Second, we cannot account for differences in coding practices at other institutions. However, our study that includes a large integrated multi-hospital health system, which increases the generalizability of our observations. Moreover, a larger variation in coding of diagnoses for SARS-CoV-2 infection surveillance would further highlight the lack of reliability of the measures.

Among hospitalized patients with COVID-19 rate of mortality to be significantly higher in hospitalized patients who had a principal diagnosis code consistent with severe manifestations . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.16.21253770 doi: medRxiv preprint of COVID-19 compared to those who had a specific principal diagnosis of COVID-19. Moreover, the use of COVID-19 diagnosis codes alone frequently misclassifies individuals with a SARS-CoV-2 infection and may not be an adequate strategy for case surveillance. Data from the EHR can provide additional data elements such as laboratory testing results that can be used to in conjunction with diagnostic codes to create more fine-tuned phenotypes that are designed for specific analytical use cases. Beijing; is a technical consultant to HugoHealth, a personal health information platform, and cofounder of Refactor Health, an AI-augmented data management platform for healthcare; is a . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation

Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study

Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection

Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19

Association of the Hospital Readmissions Reduction Program With Mortality During and After Hospitalization for Acute Myocardial Infarction, Heart Failure, and Pneumonia

Contemporary Epidemiology of Heart Failure in Fee-For-Service Medicare Beneficiaries Across Healthcare Settings

Evaluation of 30-Day Hospital Readmission and Mortality Rates Using Regression-Discontinuity Framework

Post-discharge acute care and outcomes following readmission reduction initiatives: national retrospective cohort study of Medicare beneficiaries in the United States

Temporal Trends in Heart Failure Incidence Among Medicare Beneficiaries Across Risk Factor Strata

Administrative Codes for Capturing In-Hospital Cardiac Arrest

Inaccurate ascertainment of morbidity and mortality due to influenza in administrative databases: a population-based record linkage study

Agile Health Care Analytics: Enabling Real-Time Disease Surveillance With a Computational Health Platform

Accuracy of administrative data for identifying patients with pneumonia

Validation of an algorithm based on administrative data to detect new onset of atrial fibrillation after cardiac surgery

Next-generation phenotyping of electronic health records

Assessing the accuracy of administrative data in health information systems

Accuracy of administrative data for surveillance of healthcare-associated infections: a systematic review

Health Care and Precision Medicine Research: Analysis of a Scalable Data Science Platform

Phenotype Data Acquisition

Collaborative/Phenotype_Data_Acquisition/wiki/Latest-Phenotype

The Reporting of Race and Ethnicity in Medical and Science Journals: Comments Invited

On Racism: A New Standard For Publishing On Racial Health Inequities | Health Affairs Blog

A validated, real-time prediction model for favorable outcomes in hospitalized COVID-19 patients

Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York City

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

The area under the precision-recall curve as a performance metric for rare binary events

When to consult precision-recall curves

Uptake and Accuracy of the Diagnosis Code for COVID-19 Among US Hospitalizations

Temporal relationship of computed and structured diagnoses in electronic health record data

Utilizing Medicare claims data for real-time drug safety evaluations:is it feasible?

Healthcare provider attitudes towards the problem list in an electronic health record: a mixed-methods qualitative study

Discordance of databases designed for claims payment versus clinical information systems. Implications for outcomes research

Age (mean (SD))